Stockscreener 앱 받기
0.916
4.38%
-0.042
시간 외 거래:
.94
0.024
+2.62%
Intercure Ltd 주식(INCR)의 최신 뉴스
Price to book forward of Intercure Ltd. – NASDAQ:INCR - TradingView
ETFs Investing in InterCure Ltd. Stocks - TradingView
Intercure Ltd. (INCR) Slides 3% as Support at $0.90 Comes Into FocusFibonacci Entry Signals - dars.gov.et
InterCure Ltd. Actuals & Estimates (TASE:INCR) - TradingView
Price to earnings forward of InterCure Ltd. – TASE:INCR - TradingView
InterCure Ltd. Actuals & Estimates (BOATS:INCR) - TradingView
Price to sales forward of InterCure Ltd. – TASE:INCR - TradingView
Enterprise value to EBITDA forward of InterCure Ltd. – TASE:INCR - TradingView
Intercure Ltd. (INCR) Q2 2023 Earnings: EPS Beats Estimates by 28.7% Amid Uncertain Revenue PictureEnergy Earnings Report - dars.gov.et
InterCure Secures NIS 22 Million in Private Placement Financing Led by Leading Pharma-Focused Hedge Funds - Sahm
InterCure secures $7.4M funding commitment, may rise to $18.6M - Investing.com UK
InterCure Ltd. announced that it expects to receive ILS 21.711643 million in funding from Bennu Pharma Fund Ltd and other investors. - marketscreener.com
InterCure Secures NIS 22 Million Private Placement to Fund Global Medical Cannabis Expansion - TipRanks
InterCure secures $7.4M funding commitment, may rise to $18.6M By Investing.com - Investing.com South Africa
InterCure (NASDAQ: INCR) lines up NIS 22–54 million private placement funding - Stock Titan
InterCure raises NIS 22M, with room to reach NIS 54M - Stock Titan
InterCure Ltd (INCR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
InterCure Ltd (INCR) Institutional Confidence - TradingKey
InterCure Ltd (INCR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
InterCure Ltd (INCR) Valuation: PE, PB & Fair Value Analysis - TradingKey
InterCure Ltd (INCR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
InterCure Ltd (INCR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
InterCure Ltd (INCR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
InterCure Ltd (INCR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
InterCure Ltd (INCR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
INCR Q2 2023 Earnings: EPS Surpasses Estimates on Operational StrengthEarnings Sentiment Score - Bölüm Sonu Canavarı
InterCure Advances Global Push With Botanico Acquisition Tranche and U.S. Strategy Review - The Globe and Mail
InterCure completes Botanico acquisition and expands into U.S. medical cannabis - MMJDaily
InterCure Initiates Review of US Medical Cannabis Opportunities Following Federal Rescheduling - Cannabis Business Times
InterCure completes first tranche of Botanico acquisition By Investing.com - Investing.com South Africa
InterCure Ltd. Completes First Tranche of Botanico Acquisition to Enhance International Medical Cannabis Platform - Moomoo
InterCure (NASDAQ: INCR) advances Botanico deal and eyes U.S. medical cannabis - Stock Titan
InterCure Initiates Strategic Review of U.S. Medical - GlobeNewswire
U.S. cannabis shift prompts InterCure rethink and new launches in Germany - Stock Titan
InterCure Ltd. completed the acquisition of 50% stake in Botanico Ltd. - marketscreener.com
Intercure Ltd. (INCR) Holds Near Support as Modest Gains Signal Stabilization AttemptRevenue Weighted - newsline.com
INCR Q2 2023 Earnings: EPS Surges Past Estimates by Nearly 29%, Yet Stock Sheds ValueSegment Revenue Breakdown - newsline.com
Intercure Ltd. (INCR) Q2 2023 Earnings: EPS Beats Estimates by 28.68% Amidst Revenue Uncertainty - dars.gov.et
INCR Q2 2023 Earnings: EPS Surpasses Estimates by 28.7%, Driving Stock HigherPositive Surprise Momentum - newsline.com
INCR Q2 2023 Earnings: EPS Surges Past Estimates, Stock Declines Amid Broader Market HeadwindsRevenue Surprise History - dars.gov.et
Intercure Ltd. (INCR) Q2 2023 Earnings: EPS Beat Drives 12.15% Stock SurgeEnergy Earnings Report - newsline.com
INCR Q2 2023 Earnings: EPS Surpasses Estimates by 28.68%Debt Analysis Report - The Legal Advocate
Intercure Ltd. (INCR) Q2 2023 Earnings: EPS Surges Past Estimates, Stock RalliesSurprise Factor Analysis - The Legal Advocate
Intercure Ltd. Shares Surge Over 15% as Cannabis Sector Sees Renewed InterestThrowback Trade - newsline.com
INCR Q2 2023 Earnings: EPS Surges Past Estimates as Profitability StrengthensProfit Warning Alert - The Legal Advocate
Intercure Ltd. (INCR) Rallies 5.57% as It Approaches Key Resistance LevelRSI Oversold Picks - The Legal Advocate
INCR Q2 2023 Earnings: Strong EPS Beat Highlights Operational EfficiencyEarnings Analysis - thelegaladvocate.com
INCRIntercure Ltd Stock Price and Quote - Finviz
Intercure Ltd. (INCR) Rallies 4.8%: Testing Key Resistance at $0.97Risk Reward Setups - newsline.com
INCR Q2 2023 Earnings: EPS Beat Surprises by 28.7% Despite Revenue UncertaintyShare Repurchase Impact - dars.gov.et
INCR Q2 2023 Earnings: EPS Surges Past Estimates as Company Delivers Strong Operational ResultsEarnings Trend Analysis - Newser
INCR Q2 2023 Earnings: EPS Surprises 28.68% Above Estimates Despite Negative Stock ReactionSocial Signal Watchlist - Newser
INCR (Intercure) beats Q2 estimates by 28% but shares fall 4% despite earnings surprise.AI Stock Signals - newser.com
How Intercure (INCR) performance reflects its true potential (Smart Money Flows) 2026-05-05Real Trader Insights - newser.com
InterCure Posts 2025 Revenue Growth, Positive Cash Flow as Recovery and Expansion Accelerate - The Globe and Mail
InterCure (NASDAQ: INCR) grows 2025 revenue to NIS 270M with positive cash flow - Stock Titan
1.50%
0.79%
자본화:
|
볼륨(24시간):